hVIVO (LON:HVO) Stock Passes Below Fifty Day Moving Average – Should You Sell?

hVIVO plc (LON:HVO)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 8.65 ($0.12) and traded as low as GBX 6.80 ($0.09). hVIVO shares last traded at GBX 6.80 ($0.09), with a volume of 4,562,857 shares.

Analyst Ratings Changes

Several research firms recently weighed in on HVO. Peel Hunt reissued an “add” rating and set a GBX 21 price target on shares of hVIVO in a report on Tuesday, July 29th. Shore Capital dropped their price objective on hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of GBX 23.

hVIVO Price Performance

The stock has a market capitalization of £46.73 million, a price-to-earnings ratio of 8.83 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The company has a fifty day simple moving average of GBX 8.65 and a two-hundred day simple moving average of GBX 11.58.

hVIVO (LON:HVO) last posted its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. As a group, equities research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.